Trials / Completed
CompletedNCT01834222
Post Market Surveillance to Observe Safety of Prevenar13™ in Adults
Post Marketing Surveillance To Observe Safety Of Prevenar 13 In Adults
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 659 (actual)
- Sponsor
- Pfizer · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to assess safety profile of Prevenar 13™ when used among Korean adults in the routine clinical setting, as required for any new drug approved by Korea Food and Drug Administration (KFDA).
Detailed description
non-randomization, non-probability sampling
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Non-intervention | Non-intervention |
Timeline
- Start date
- 2013-12-01
- Primary completion
- 2016-03-01
- Completion
- 2016-03-01
- First posted
- 2013-04-17
- Last updated
- 2017-04-18
- Results posted
- 2017-04-18
Locations
27 sites across 1 country: South Korea
Source: ClinicalTrials.gov record NCT01834222. Inclusion in this directory is not an endorsement.